Jan Mikkelsen
Fondateur chez ASCENDIS PHARMA A/S
Fortune : 58 M $ au 30/06/2024
Profil
M. Jan M. Mikkelsen est directeur général et directeur d'Ascendis Pharma Endocrinology Division A/S, président, directeur général et directeur exécutif d'Ascendis Pharma A/S, directeur général d'Ascendis Pharma Bone Diseases A/S et directeur général d'Ascendis Pharma Growth Disorders AS. Il est membre du conseil d'administration d'Ascendis Pharma Endocrinology Division A/S, d'Ascendis Pharma A/S et de Visen Pharmaceuticals (Shanghai) Co. Ltd. Auparavant, M. Mikkelsen a occupé les postes de président-directeur général de LifeCycle Pharma A/S, de président de la division pharmaceutique de Maxygen, Inc. et de co-président-directeur général de Profound Pharma AS, ainsi que de vice-président de la découverte de protéines chez Novo Nordisk A/S. Il a obtenu son diplôme de premier cycle à l'université du Danemark du Sud.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ASCENDIS PHARMA A/S
0,89% | 31/12/2023 | 423 279 ( 0,89% ) | 58 M $ | 30/06/2024 |
Postes actifs de Jan Mikkelsen
| Sociétés | Poste | Début |
|---|---|---|
| ASCENDIS PHARMA A/S | Fondateur | 01/09/2006 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Directeur Général | 29/06/2012 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Directeur/Membre du Conseil | - |
| Ascendis Pharma Bone Diseases A/S | Directeur Général | - |
| Ascendis Pharma Growth Disorders AS | Directeur Général | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | 01/01/2022 |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Directeur/Membre du Conseil | 07/11/2018 |
| Hummingbird Bioscience Holdings Pte Ltd. | Président | 01/01/2021 |
Anciens postes connus de Jan Mikkelsen
| Sociétés | Poste | Fin |
|---|---|---|
| VELOXIS PHARMACEUTICALS A/S | Directeur Général | 01/01/2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jan Mikkelsen
| University of Southern Denmark | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| NOVO NORDISK A/S | Health Technology |
| Entreprise privées | 10 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million. | Health Technology |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Health Technology |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Health Technology |
| Ascendis Pharma Bone Diseases A/S | |
| Ascendis Pharma Growth Disorders AS | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Finance |
VISEN Pharmaceuticals
VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Health Technology |
| Hummingbird Bioscience Holdings Pte Ltd. |
